Novartis's Entresto Receives US FDA's Approval for Chronic Heart Failure
Shots:
- The approval is based on P-III PARAGON-HF study involves assessing of Entresto (sacubitril/valsartan) in the treatment of patients with preserved ejection fraction HFpEF
- The expanded indication enables potential treatment of adults with left ventricular ejection fraction (LVEF) below normal- benefits are most clearly evident
- Entresto is the 1st and only therapy approved in the US to treat patients diagnosed with guideline defined heart failure to include both those with HFrEF and many with HFpEF
Ref: Novartis | Image: Novartis
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com